💊
Hepsera
adefovir dipivoxil
Chronische hepatitis B
🚫 Ingetrokken
✅
Geen actieve meldingen
Dit geneesmiddel heeft geen lopende tekorten, veiligheidsbrieven of terugroepacties.
Waarvoor het wordt gebruikt
Hepsera is indicated for the treatment of chronic hepatitis B in adults with: compensated liver disease with evidence of active viral replication, persistently elevated serum-alanine-aminotransferase (ALT) levels and histological evidence of active liver inflammation and fibrosis. Initiation of Hepsera treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate (see section 5.1); decompensated liver disease in combination with a second agent without cross-resistance to Hepsera.
⚠️ Patiëntveiligheid
No
Officiële EMA-pagina
https://www.ema.europa.eu/en/medicines/human/EPAR/hepsera